Case studies

Therapy areas

Case Study

Forecasting global value assessments for a rare-disease drug

Case Study

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (…

Case Study

Determination of the acceptability of specific endpoints in adjuvant treatment of EGFRm …

Case Study

Global HTA/P&R review for CAR-Ts in rare oncological diseases

Case Study

A lexicon of “cure” for internal alignment and external discussions in oncology

Case Study

Shaping stakeholder perspectives on the long-term clinical benefit of immuno-oncologic therapies

Case Study

Value assessment and integrated evidence generation planning in Asia-Pacific: a case study …

Case Study

Real-world example: a PIE program with US payers to support preliminary access …

Case Study

Early scientific advice support for an orphan drug for a rare cardiovascular …

Case Study

Accelerating the submission process for 16 markets through simultaneous development of HTA dossiers

Case Study

Strategic overview of hepatitis B vaccine policy environment for inclusion in a …

Case Study

Disease area review of psoriasis and global value dossier for an immunological …

Case Study

Evaluating the evidence requirements to support the market access of a novel …

Case Study

Development of payer materials for a schizophrenia treatment

Case Study

Mapping orphan drug policies and pathways across 12 markets

Case Study

Development of a GVD aligned with core content requirements of local payer …

Case Study

Landscape assessment to inform trial design and payer value positioning using the …

Case Study

Value assessment and integrated evidence generation planning for mental health assets

Case Study

Market access roadmap for an ultra-orphan drug for a genetic cardiovascular disorder

Case Study

Payer risk assessment and evidence generation planning using the PRMA Healthcheck^®

Case Study

The PRMA Navigator^® digital application auto‑generates HTA submissions for …

Case Study

Market access and pricing opportunity for an asset in development for a …

Case Study

Early scientific advice for a product in development for a rare cardiovascular …

Case Study

Managed entry agreement frameworks for rare disease products

Case Study

Market access roadmap in hemophilia B

Case Study

Proactively managing HTA challenges for follow-on indications in an orphan disease

Case Study

Developing an economic model to optimize market access opportunities

Case Study

Developing an international market access strategy to optimize pricing and reimbursement opportunities

Case Study

Developing a market access and HEOR roadmap in a rapidly evolving landscape

Case Study

Creating compelling real-world evidence that supports favorable HTA

Case Study

Blocking competitor intrusion in competitive pharmaceutical markets

Case Study

Achieving a positive HTA outcome with insight from payer and clinician advisory …

Case Study

Accelerating decision-making for international market access

Case Study

Recommendations for an ophthalmology launch plan in the EU

Case Study

Using payer perspectives to inform evidence generation strategies for successful market access

Services

Case Study

Forecasting global value assessments for a rare-disease drug

Case Study

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (…

Case Study

Determination of the acceptability of specific endpoints in adjuvant treatment of EGFRm …

Case Study

Global HTA/P&R review for CAR-Ts in rare oncological diseases

Case Study

A lexicon of “cure” for internal alignment and external discussions in oncology

Case Study

Shaping stakeholder perspectives on the long-term clinical benefit of immuno-oncologic therapies

Case Study

Value assessment and integrated evidence generation planning in Asia-Pacific: a case study …

Case Study

Real-world example: a PIE program with US payers to support preliminary access …

Case Study

Early scientific advice support for an orphan drug for a rare cardiovascular …

Case Study

Accelerating the submission process for 16 markets through simultaneous development of HTA dossiers

Case Study

Strategic overview of hepatitis B vaccine policy environment for inclusion in a …

Case Study

Disease area review of psoriasis and global value dossier for an immunological …

Case Study

Evaluating the evidence requirements to support the market access of a novel …

Case Study

Development of payer materials for a schizophrenia treatment

Case Study

Mapping orphan drug policies and pathways across 12 markets

Case Study

Implications of a companion diagnostic test for market access of a novel …

Case Study

Development of a GVD aligned with core content requirements of local payer …

Case Study

Landscape assessment to inform trial design and payer value positioning using the …

Case Study

Value assessment and integrated evidence generation planning for mental health assets

Case Study

Market access roadmap for an ultra-orphan drug for a genetic cardiovascular disorder

Case Study

Payer risk assessment and evidence generation planning using the PRMA Healthcheck^®

Case Study

The PRMA Navigator^® digital application auto‑generates HTA submissions for …

Case Study

Market access and pricing opportunity for an asset in development for a …

Case Study

Early scientific advice for a product in development for a rare cardiovascular …

Case Study

Managed entry agreement frameworks for rare disease products

Case Study

Partnership with client’s Asia-Pacific team on regional activity and evidence roadmaps

Case Study

Framework to assess the early commercial and market access potential of an …

Case Study

Assessment framework of access landscape, reimbursement, and development plan for early pipeline …

Case Study

Co-creation of a value assessment framework for early assets in the Asia-Pacific …

Case Study

Up to 30% of global HTA template requirements may not be met by …

Case Study

Emerging biomarker in a hemato-oncology indication

Case Study

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Case Study

This top-5 pharma company chose the PRMA Navigator® to accelerate the generation …

Case Study

Estimating the eligible patient population for a targeted oncology therapy

Case Study

Development of a value story, GVD, and payer materials

Case Study

Critically evaluating pricing and access risks and opportunities for an asset under …

Case Study

Maximize the pricing and market access potential of your early pipeline

Case Study

Improving pharmaceutical portfolio management and decision-making for early assets

Case Study

Evidence synthesis and development of economic models

Case Study

Combinations: P&R considerations

Case Study

Improve health technology assessment submissions

Case Study

Demonstrating value using a new approach to economic modeling

Case Study

Identifying critical risks for payer decision-making

Case Study

Anticipate evidence needs early on and accelerate development of focused evidence generation …

Case Study

Assessing evidence generation strategies for an asset with a novel biomarker in …

Case Study

Bolstering payer discussions to solve persistent challenges

Case Study

Strategic roadmap for optimized global market access for CAR-T

Case Study

Landscape assessments and market access strategy for CDx-drug pairings

Case Study

Strategic projects to inform commercialization decisions in RSV

Case Study

Strategic and tactical support achieves HTA success

Case Study

Digitally transforming health technology assessment (HTA) submission processes

Case Study

Value frameworks scoring of a new oncology treatment and comparators

Digital applications

Case Study

Development of a GVD aligned with core content requirements of local payer …

Case Study

Landscape assessment to inform trial design and payer value positioning using the …

Case Study

Value assessment and integrated evidence generation planning for mental health assets

Case Study

Payer risk assessment and evidence generation planning using the PRMA Healthcheck^®

Case Study

Healthcheck assessment for novel asset in moderate to severe rheumatoid arthritis

Case Study

This top-5 pharma company chose the PRMA Navigator® to accelerate the generation …

Case Study

Development of a value story, GVD, and payer materials

Case Study

Critically evaluating pricing and access risks and opportunities for an asset under …

Case Study

Maximize the pricing and market access potential of your early pipeline

Case Study

Improving pharmaceutical portfolio management and decision-making for early assets

Case Study

Improve health technology assessment submissions

Case Study

Demonstrating value using a new approach to economic modeling

Case Study

Top-5 pharma discovers a new way to evaluate pricing opportunities

Case Study

Identifying critical risks for payer decision-making

Case Study

Anticipate evidence needs early on and accelerate development of focused evidence generation …

Case Study

Assessing evidence generation strategies for an asset with a novel biomarker in …

Case Study

Bolstering payer discussions to solve persistent challenges

Please contact us for more information